Advisory Research’s Cymabay Therapeutics CBAY Stock Holding History

Advisory Research’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-98,985	Closed	-$2.34M	–	342
2023 Q4	$2.34M	Sell	98,985 -5,555	-5%	-$98.9K	0.36%	74
2023 Q3	$1.56M	Sell	104,540 -17,693	-14%	-$235K	0.22%	131
2023 Q2	$1.34M	Buy	+122,233	New	+$1.14M	0.17%	163

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Advisory Research's CBAY Position: Q1 2024 in Review

Advisory Research sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 98,985 shares — an estimated $2.34M sold.

Advisory Research first reported a position in CBAY in Q2 2023 and held it in 3 quarters. The position peaked at $2.34M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Advisory Research reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Advisory Research sold 98,985 Cymabay Therapeutics shares in Q1 2024, an estimated $2.34M.
Advisory Research first reported a position in Cymabay Therapeutics in Q2 2023 and held it in 3 quarters.
Advisory Research's Cymabay Therapeutics position peaked at $2.34M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.